About: CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization
Creator	Champion, Brian Cockle, Paul Khodai, Tansi Mirza, Fareed Perez-Tosar, Luis Webster, Rob Bright, Helen Hickling, Timothy Platt, Rebecca Townend, Tim
source	Medline; PMC
abstract	CD8+ T cells have the potential to control HSV-2 infection. However, limited information has been available on CD8+ T cell epitopes or the functionality of antigen specific T cells during infection or following immunization with experimental vaccines. Peptide panels from HSV-2 proteins ICP27, VP22 and VP13/14 were selected from in silico predictions of binding to human HLA-A0201 and mouse H-2Kd, Ld and Dd molecules. Nine previously uncharacterized CD8+ T cell epitopes were identified from HSV-2 infected BALB/c mice. HSV-2 specific peptide sequences stabilized HLA-A02 surface expression with intermediate or high affinity binding. Peptide specific CD8+ human T cell lines from peripheral blood lymphocytes were generated from a HLA-A*02+ donor. High frequencies of peptide specific CD8+ T cell responses were elicited in mice by DNA vaccination with ICP27, VP22 and VP13/14, as demonstrated by CD107a mobilization. Vaccine driven T cell responses displayed a more focused immune response than those induced by viral infection. Furthermore, vaccination with ICP27 reduced viral shedding and reduced the clinical impact of disease. In conclusion, this study describes novel HSV-2 epitopes eliciting strong CD8+ T cell responses that may facilitate epitope based vaccine design and aid immunomonitoring of antigen specific T cell frequencies in preclinical and clinical settings.
has issue date	2013-01-04(xsd:dateTime)
bibo:doi	10.3390/cells2010019
bibo:pmid	24709642
has license	cc-by
sha1sum (hex)	de95f39159534068d4a1aef3e5d6a884d1c39656
schema:url	https://doi.org/10.3390/cells2010019
resource representing a document's title	CD8+ T Lymphocyte Epitopes From The Herpes Simplex Virus Type 2 ICP27, VP22 and VP13/14 Proteins To Facilitate Vaccine Design And Characterization
has PubMed Central identifier	PMC3972665
has PubMed identifier	24709642
schema:publication	Cells
resource representing a document's body	covid:de95f39159534068d4a1aef3e5d6a884d1c39656#body_text
is schema:about of	named entity 'CD8' named entity 'EPITOPES' named entity 'VACCINES' named entity 'LIMITED' named entity 'EXPRESSION' named entity 'STABILIZED' named entity 'HLA-A' named entity 'ELICITED' named entity 'T CELLS' named entity 'MICE' named entity 'SPECIFIC' named entity 'HSV-2 INFECTION' named entity 'HIGH' named entity 'CELL LINES' named entity 'T LYMPHOCYTE' named entity 'INFORMATION' named entity 'FUNCTIONALITY' named entity 'POTENTIAL' named entity 'MOUSE' named entity 'INFECTED' named entity 'GENERATED' named entity 'ANTIGEN SPECIFIC' named entity 'SURFACE' named entity 'SELECTED' named entity 'CD8' named entity 'DONOR' named entity 'T CELL' named entity 'HSV-2' named entity 'EPITOPES' named entity 'IDENTIFIED' named entity 'EXPERIMENTAL' named entity 'CD107A' named entity 'PEPTIDE' named entity 'HUMAN T CELL' named entity 'HERPES SIMPLEX VIRUS TYPE 2' named entity 'CHARACTERIZATION' named entity 'ICP27' named entity 'VACCINE DESIGN' named entity 'PROTEINS' named entity 'TO CONTROL' named entity 'INFECTION' named entity 'PREDICTIONS' named entity 'AVAILABLE' named entity 'PROTEINS' named entity 'HUMAN' named entity 'PREVIOUSLY' named entity 'INTERMEDIATE' named entity 'ICP27' named entity 'HAVE' named entity 'SEQUENCES' named entity 'MOLECULES' named entity 'AFFINITY' named entity 'FOLLOWING' named entity 'IN SILICO' named entity 'FREQUENCIES' named entity 'BINDING' named entity 'DNA VACCINATION' named entity 'PANELS' named entity 'IMMUNIZATION' named entity 'BALB' named entity 'RESPONSES' named entity 'PERIPHERAL BLOOD LYMPHOCYTES' covid:arg/de95f39159534068d4a1aef3e5d6a884d1c39656 named entity 'vaccines' named entity 'epitopes' named entity 'CD107a' named entity 'peripheral blood lymphocytes' named entity 'CD8+ T cells' named entity 'DNA vaccination' named entity 'mice' named entity 'CD8+' named entity 'Epitopes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software